Liminatus Pharma logo
Liminatus Pharma
LIMN | NASDAQ
Chart Builder DCF Calculator
$3.04
+$0.05 (+1.67%)
At close: Nov 16, 2026, 3:59 PM ET
$2.99
-$0.05 (-1.58%)
After-hours: Nov 16, 2026, 7:41 PM ET

Liminatus Pharma Company Profile

Company profile explained

Company Profile

Liminatus Pharma, Inc. is an immuno-oncology firm, currently in its clinical development phase, dedicated to pioneering new treatments for cancer. The company's headquarters are located in La Palma, California.

Key Executives

Name Position
Chris Kim CEO, Chairman & President
Beom Kyu Choi Chief Technology Officer & Member of Scientific Advisory Board
Scott Dam Chief Financial Officer
Byong Chul Yoo Chief Science Officer & Member of Scientific Advisory Board

Latest SEC Filings

Date Type Title
Sep 29, 2026 8-K Current Report
Aug 18, 2026 8-K Current Report
Aug 14, 2026 10-Q Quarterly Report
Aug 04, 2026 8-K Current Report
Jul 30, 2026 8-K Current Report
Jul 24, 2026 8-K Current Report
Jul 22, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Jul 14, 2026 4 Filing
Jul 14, 2026 SC 13D/A [Amend] Filing
Jul 13, 2026 DEF 14A Filing
View All SEC Filings ➞
Liminatus Pharma
Liminatus Pharma logo
Country United States
IPO Date May 1, 2025
Industry Biotechnology
Sector Healthcare
Employees 1
CEO Chris Kim

Contact Details

12611 Hiddencreek Way Cerritos, California 90703 United States

Stock Details

Ticker Symbol LIMN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001971387
CUSIP Number 53271X207
ISIN Number US53271X2071
SIC Code 2836

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.